Katharine Peterson

CIK: 0002022214

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (9.1%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (27.3%)

Compensation grants

Other (G, F, J, C, D, …)7 (63.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ACRV

Acrivon Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

ACRV
Acrivon Therapeutics, Inc.
Aug 18, 2026
Sale(S)
Direct
101 shares at avg. $2.01$203.01
ACRV
Acrivon Therapeutics, Inc.
May 18, 2026
Award(A)
Direct
14.2K shares-
ACRV
Acrivon Therapeutics, Inc.
May 14, 2026
Tax Payment(F)
Direct
99 shares at avg. $1.92$190.08
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2026
Award(A)
Stock Option (Right to Buy)
Direct
31.9K shares-
ACRV
Acrivon Therapeutics, Inc.
Feb 14, 2026
Tax Payment(F)
Direct
116 shares at avg. $1.63$189.08
ACRV
Acrivon Therapeutics, Inc.
Nov 14, 2025
Tax Payment(F)
Direct
99 shares at avg. $2.24$221.76
ACRV
Acrivon Therapeutics, Inc.
Aug 14, 2025
Tax Payment(F)
Direct
99 shares at avg. $1.39$137.61
ACRV
Acrivon Therapeutics, Inc.
May 14, 2025
Tax Payment(F)
Direct
99 shares at avg. $1.14$112.86
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
31.9K shares-
ACRV
Acrivon Therapeutics, Inc.
Feb 14, 2025
Tax Payment(F)
Direct
116 shares at avg. $5.42$628.72
ACRV
Acrivon Therapeutics, Inc.
Nov 14, 2024
Tax Payment(F)
Direct
99 shares at avg. $7.92$784.08

		Type	Shares	Price		Ownership
Aug 18, 2026	ACRV Acrivon Therapeutics, Inc.	Sale(S)	101	$2.01	$203	Direct
May 18, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A)	14,227	-	$0	Direct
May 14, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	99	$1.92	$190	Direct
Mar 1, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	31,900	-	-	Direct
Feb 14, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	116	$1.63	$189	Direct
Nov 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	99	$2.24	$222	Direct
Aug 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	99	$1.39	$138	Direct
May 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	99	$1.14	$113	Direct
Mar 1, 2025	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	31,900	-	-	Direct
Feb 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	116	$5.42	$629	Direct
Nov 14, 2024	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	99	$7.92	$784	Direct

1-11 of 11 transactions

About Peterson Katharine

Peterson Katharine (SEC CIK 0002022214) files insider reports with the SEC as Chief Accounting Officer of Acrivon Therapeutics, Inc. (ACRV).

Signal8 holds 11 ownership filings by Peterson Katharine, all Form 4s, filed between Nov 18, 2024 and Aug 20, 2026. Those filings report 11 transactions, from Nov 14, 2024 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Peterson Katharine's filings is in WATERTOWN, MA.

Recent filings by Peterson Katharine

Aug 18, 2026: Open-market sale of ACRV shares (Form 4, code S).
May 18, 2026: Grant or award of ACRV shares (Form 4, code A).
May 14, 2026: Tax withholding of ACRV shares (Form 4, code F).
Mar 1, 2026: Grant or award of ACRV derivative securities (Form 4, code A).
Feb 14, 2026: Tax withholding of ACRV shares (Form 4, code F).

Other insiders filing for Acrivon Therapeutics, Inc. (ACRV)

Miller Mary, Chief Legal Officer
Levin Michaela, Chief Business Officer
Blume-Jensen Peter, President and CEO
Gamelin Erick, Chief Development Officer
Devroe Eric, Chief Operating Officer
Levy Adam D., Chief Financial Officer

How to read Form 4 transaction codes